The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
UK-based Senisca, a biotech company developing RNA-based therapeutics to reverse cellular senescence and target age-related disease, has announced an expansion of its leadership team. 18 May 2023
USA-based ophthalmic diseases specialist EyePoint Pharmaceuticals saw its share leap 15.4% to $7.40 in pre-market trading today, as it announced a definitive agreement for the sale of Yutiq (fluocinolone acetonide intravitreal implant) 0.18mg to Alimera Sciences. 18 May 2023
Shares of US drug developer Intercept Pharmaceuticals closed down 14.7% at $13.83 yesterday, after the US Food and Drug Administration released briefing document ahead of the FDA’s Gastrointestinal Drugs Advisory Committee. 18 May 2023
US biotech Novavax’ COVID-influenza combination (CIC) vaccine reflects a wider industry trend for increased usage of artificial intelligence (AI) in clinical trial design, says data and analytics company GlobalData. 18 May 2023
Not-for-profit UK medical research organization LifeArc and techbio company PrecisionLife have announced a strategic R&D collaboration to accelerate the discovery and development of targeted treatments for amyotrophic lateral sclerosis (ALS), a disease also known as motor neurone disease. 17 May 2023
The US Food and Drug Administration (FDA) has accepted Japanese pharma major Takeda’s Biologics License Application (BLA) for TAK-755, an enzyme replacement therapy for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP), an ADAMTS13 deficiency disorder, for priority review. 17 May 2023
Gilead Sciences has announced that Cindy Perettie will join the firm as executive vice president of its subsidiary company Kite, overseeing the cell therapy business. 17 May 2023
Scientists at the US Food and Drug Administration have outlined a positive stance towards an RSV vaccine developed by Pfizer, ahead of a formal meeting to discuss the firm’s regulatory submission for the candidate. 17 May 2023
Some positive data from Coya Therapeutics lifted the US biotech’s shares 10% in normal trading and a further 6.4% to $6.20 in after-hours activity on Tuesday. 17 May 2023
Positive results from the Phase II FENopta study evaluating investigational oral fenebrutinib in adults with relapsing forms of multiple sclerosis (RMS) have been released by Swiss pharma giant Roche. 17 May 2023
New late-stage data from the FLAURA2 trial confirm the treatment potential for Tagrisso (osimertinib), while underscoring the value of targeted therapies for certain kinds of lung cancer. 17 May 2023
Boundless Bio, a US precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) for oncogene amplified cancers, has announced the closing of a $100 million Series C financing. 16 May 2023
As soon as US biotech giant Amgen announced that it is to acquire Horizon Therapeutics in a deal worth $27.8 billion, concerns were voiced that the US competition regulator would take a serious look at monopoly and anti-competitiveness implications. 16 May 2023
Much has been made of the sudden rise in sales of Wegovy (semaglutide) and the weight loss drug’s impact in driving rapid growth at Novo Nordisk. 16 May 2023
Dermavant Sciences, an immuno-dermatology-focused subsidiary of Switzerland-based Roivant Sciences, today announced positive results from ADORING 1, the second of two double-blind, randomized, vehicle-controlled Phase III studies to evaluate the efficacy and safety of topical Vtama (tapinarof) cream. 16 May 2023